Integra LifeSciences Holdings Corporation logo

Integra LifeSciences Holdings Corporation (IL3)

Market Closed
12 Dec, 20:00
XDUS XDUS
11. 40
-0.3
-2.56%
- Market Cap
37.88 P/E Ratio
0% Div Yield
0 Volume
3.21 Eps
11.7
Previous Close
Day Range
11.4 11.8
Year Range
9.4 25.6
Want to track IL3 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 73 days

Summary

IL3 closed today lower at €11.4, a decrease of 2.56% from yesterday's close, completing a monthly increase of 2.7% or €0.3. Over the past 12 months, IL3 stock lost -47.22%.
IL3 is not paying dividends to its shareholders.
The last earnings report, released on Oct 30, 2025, exceeded the consensus estimates by 0.11%. On average, the company has fell short of earnings expectations by -0.07%, based on the last three reports. The next scheduled earnings report is due on Feb 24, 2026.
Integra LifeSciences Holdings Corporation has completed 4 stock splits, with the recent split occurring on Jan 04, 2017.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

IL3 Chart

Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seekingalpha | 1 week ago
Integra LifeSciences Holdings Corporation (IART) Q3 2025 Earnings Call Transcript

Integra LifeSciences Holdings Corporation (IART) Q3 2025 Earnings Call Transcript

Integra LifeSciences Holdings Corporation ( IART ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christopher Ward - Senior Director of Investor Relations Mojdeh Poul - President, CEO & Director Lea Knight - Executive VP & CFO Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Presentation Operator Good day, and welcome to the Integra LifeSciences Third Quarter 2025 Financial Results. [Operator Instructions] As a reminder, this call may be recorded.

Seekingalpha | 1 month ago
Integra (IART) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Integra (IART) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 1 month ago

Integra LifeSciences Holdings Corporation (IL3) FAQ

What is the stock price today?

The current price is €11.40.

On which exchange is it traded?

Integra LifeSciences Holdings Corporation is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is IL3.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.8.

When is the next earnings date?

The next earnings report will release on Feb 24, 2026.

Has Integra LifeSciences Holdings Corporation ever had a stock split?

Integra LifeSciences Holdings Corporation had 4 splits and the recent split was on Jan 04, 2017.

Integra LifeSciences Holdings Corporation Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Mojdeh Poul CEO
XDUS Exchange
US4579852082 ISIN
US Country
4,396 Employees
- Last Dividend
1 Jul 2015 Last Split
16 Aug 1995 IPO Date

Overview

Founded in 1989 and headquartered in Princeton, New Jersey, Integra LifeSciences Holdings Corporation stands as a pioneering entity in the medical device industry. The company thrives on manufacturing and marketing an array of surgical instruments, neurosurgical products, and advanced wound care products that cater to specialized fields like neurosurgery, neurocritical care, and otolaryngology. Integra LifeSciences operates through two primary divisions: Codman Specialty Surgical and Tissue Technologies. These divisions underscore the company’s commitment to innovation, quality, and patient care by offering cutting-edge products and services that address critical needs across various healthcare settings. By maintaining a direct sales force and a network of distribution channels, Integra LifeSciences ensures its offerings are accessible to hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, as well as dental, podiatry, and veterinary practices across the United States, Europe, Asia Pacific, and other international markets.

Products and Services

  • Neurosurgery and Neurocritical Care Products

    Integra offers a comprehensive range of products for neurosurgery and neurocritical care, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. These products are essential for surgeries and treatments related to the brain, spinal cord, and other components of the nervous system, seeking to improve patient outcomes through precision and reliability.

  • Surgical Instruments and Headlamps

    The company also specializes in high-quality surgical instruments and surgical headlamps, designed to aid in various surgical procedures across specialties. Coupled with an array of after-market services, these products ensure clinicians have access to durable, precise tools for a plethora of medical procedures, enhancing operative efficiency and patient safety.

  • Regenerative Technology Products

    Focused on the healing of acute wounds, Integra’s regenerative technology products span advanced solutions that promote the body's natural healing processes. These products are instrumental in treating complex wounds, driving faster recovery times, and improving the quality of life for patients enduring acute wound challenges.

  • Surgical Tissue Repair Products

    Addressing needs in hernia, tendon, and peripheral nerve repair and protection, Integra's surgical tissue repair products are at the forefront of surgical innovation. These offerings leverage the latest advancements in medical technology to provide effective, minimally invasive solutions for tissue repair, aiding in the restoration of function and preventing further injury.

  • Skin and Wound Repair, Plastics, and Surgical Reconstruction

    Integra's portfolio also includes products for skin and wound repair, alongside solutions for plastics and surgical reconstruction. Whether it's bone grafts or nerve and tendon repair products, the company delivers a broad spectrum of materials and technologies designed to aid in the repair, reconstruction, and enhancement of patient structural integrity and function post-surgery or injury.

Contact Information

Address: 1100 Campus Road
Phone: 609 275 0500